OmniAb, Inc. reported significant financial improvements in its latest quarterly results, with total revenue reaching $14.4 million for the three months ended March 31, 2026, compared to $4.2 million in the same period last year, marking a 247% increase. The surge in revenue was primarily driven by a substantial rise in license and milestone revenue, which increased to $12.0 million from $2.0 million, reflecting a 495% growth. Service revenue also saw a modest increase of 11%, rising to $2.1 million, while royalty revenue grew by 28% to $241,000. Despite these gains, the company reported a net loss of $7.7 million, an improvement from the $18.2 million loss recorded in the prior year.
In terms of operational metrics, OmniAb maintained 107 active partners and reported 409 active programs utilizing its technology platform, which includes 27 antibodies in clinical development. The company’s strategic focus on expanding its partner base and enhancing its technology offerings appears to be yielding positive results, as evidenced by the increase in active programs from 407 at the end of 2025. The company’s employee headcount remained stable, supporting its ongoing research and development efforts.
OmniAb's total operating expenses for the quarter were $22.3 million, slightly down from $23.0 million a year earlier. Research and development expenses decreased by 24% to $9.6 million, attributed to lower personnel costs and reduced external expenses related to ion channel programs. General and administrative expenses also fell by 16% to $6.6 million, reflecting cost management efforts. However, amortization of intangibles rose significantly due to a $2.9 million impairment charge related to certain legacy small molecule ion channel assets.
The company’s cash and cash equivalents, along with short-term investments, totaled $49.1 million as of March 31, 2026, providing a solid liquidity position to support operations for at least the next 12 months. OmniAb has indicated that it may seek additional capital in the future to expand its business and pursue strategic investments. The company is also exploring opportunities to leverage its existing cash reserves and potential future revenues from milestone payments and royalties as it continues to develop its technology platform and expand its market presence.
Looking ahead, OmniAb remains optimistic about its growth trajectory, emphasizing the potential for increased revenue from milestone payments and royalties as its partners advance their therapeutic programs. The company’s strategic initiatives, including the ongoing development of its proprietary technologies and expansion of its partner network, are expected to drive long-term value, although the timing and realization of royalty payments remain uncertain.
About OmniAb, Inc.
OmniAb, Inc. licenses advanced antibody discovery technologies utilizing genetically engineered transgenic animals and AI-driven screening platforms. Its core offerings include diverse fully human antibody repertoires, high-throughput B cell screening, and bispecific antibody platforms. Serving pharmaceutical, biotech, and academic clients worldwide, OmniAb accelerates therapeutic development across multiple modalities, including antibodies, bispecifics, and ion channel targets, leveraging proprietary animal models and computational tools for efficient, high-quality drug candidate identification.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.